March 20, 2023

ProVascTec, an NLC venture, will help patients  with critical limb ischemia by triggering cell induced new vascular tissue growth.   

Atherosclerosis describes the build-up of fats, cholesterol and other substances within the inner arterial  walls. This build-up, also called plaque, can cause arteries to narrow and eventually completely block the arterial blood flow. If the occlusion is located in the patient’s limbs, the disease is referred to as peripheral arterial disease (PAD). Untreated PAD can progress to become critical limb ischemia (CLI). 

Typical symptoms of PAD include leg pain when walking, or claudication and decreased blood perfusion in the affected limbs. If PAD is not treated, it can progress to CLI with typical symptoms like rest pain, dying tissue from insufficient blood flow (gangrene) and non-healing open wounds (ulcers). CLI typically is treated by mechanically removing or circumventing the occlusion in the arteries using angioplasty/stents or open surgical bypasses. Both treatment options suffer from short- and long-term complications, requiring improvements of the current standard of care.

ProVascTec’s approach  changes the treatment paradigm for CLI by going around the obstruction rather than through it. ProVascTec’s cell therapy is delivered via a proprietary device to generate a new vascular structure around the obstruction through the recruitment of  local microvessels.  ProVascTec will initially focus on applications below the knee, BTK, where no treatment is currently approved.

Dr. Holger Müller, CFA, CEO & Co-Founder of ProVascTec: “Developing a novel treatment for patients who might otherwise face an amputation of all or part of their limbs is a true motivator to make this technology available”.

 Dr. Holger  Müller, a scientist at heart, studied chemistry in Germany and England and completed his education with a Ph.D. at the ETH Zürich. He started his professional career at Bain Company, before joining Novartis. While at Novartis, Holger held various marketing, sales, and business development positions of increasing responsibility, both at headquarter- and local affiliate level. After a career of 10 years, Holger joined the pioneering cell therapy company Cell Medica (now Athenex) as SVP Commercial Operations. He expanded on his start-up experience as Chief Commercial Officer for Biognosys and Chief Operating Officer at Spiden, before joining Health Advances, a global life science consultancy where he led the European office before joining ProVascTec. ProVascTec’s leadership team is completed by the inventor and co-founder, Prof. Dr. Noel Caplice  and Taco Van Der Feltz, NLC ventures.. Prof. Caplice comes with 25 years of Clinician Scientist experience formerly at Mayo Clinic, Rochester, MN and now at University College Cork where he runs a translational lab in vascular biology. He is an academic interventional cardiologist, a serial inventor with multiple patents and a track record in translating bench concepts to first in man clinical trials. Noel will serve as Chief Scientific Officer. 

The project is currently in the preclinical stage.


About NLC
NLC is the leading European healthtech venture builder. NLC identifies top-notch early-stage healthcare inventions and brings them to market, acting as the connecting link between technology innovation and entrepreneurship in medtech, biotech and digital health. To optimize patient care and enhance its positive and sustainable impact, NLC collaborates with corporates such as Philips and healthcare and academic research institutions such as Oxford University and Mayo Clinic.

NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, 17. With its growing team of more than 80 professionals and over 110 portfolio ventures built across 11 European countries, NLC is currently expanding its impact-driven operations to the US and the Gulf region.



NLC – The European Venture Builder
Anne Reijns
Marketing & Communications Lead

Holger Müller, CFA – CEO & Co-Founder

NLC Health Ventures Footer